Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2023-05-08 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the Ontario Securities Commission has issued a cease trade order due to the company's failure to file its audited financial statements and related filings for the fiscal year ended December 31, 2023. It explains the reasons for the delay and the anticipated timing for filing the required documents. The document does not contain the actual audited financial statements, management discussion and analysis, or certifications themselves, but rather announces the regulatory action and the status of the filings. It is a regulatory announcement about a compliance issue rather than a financial report or filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a $2.31 million private placement financing by HydroGraph Clean Power Inc. It details the terms of the private placement, including the number of units issued, pricing, warrants, use of proceeds, and regulatory exemptions relied upon. There is no financial statement data or comprehensive financial analysis present. The document is focused on capital raising activity and financing update rather than a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed financing information, supporting a high confidence classification.
2023-04-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a research collaboration agreement between PharmaDrug and PharmaTher for the development of a DMT transdermal patch. It discusses the company's research programs, partnerships, and forward-looking statements about future clinical studies and regulatory plans. There are no financial statements, earnings data, regulatory certifications, or detailed management discussions of financial results. The content is primarily a corporate announcement about a collaboration and development plan, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation or voting announcement. Given the nature of the document as a corporate news release about a collaboration and development update, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-02-22 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of an option agreement to acquire a mining project. It details the terms of the option agreement, payment schedule, work obligations, and royalty terms. There are no financial statements, regulatory certifications, or detailed financial performance data. The content focuses on a capital acquisition transaction related to mining property rights and option payments. This fits the category of Capital/Financing Update (CAP), as it relates to the company's financing activities and capital commitments for acquiring an asset. The document length is moderate and contains substantive information about the financing arrangement rather than just an announcement of a report or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2023-02-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing PharmaDrug's plans to initiate a first-in-human clinical study for their drug candidate PD-001 in esophageal cancer. It discusses the clinical development strategy, regulatory considerations, preclinical study results, and forward-looking statements about the drug's potential and development timeline. There are no financial statements, earnings data, management discussion of financial results, or regulatory filings related to financial performance. The content is focused on clinical trial plans and drug development updates, typical of a corporate announcement or news release rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content as a corporate announcement about clinical study plans, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2023-02-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of a PCT (Patent Cooperation Treaty) application for a pharmaceutical product (PD-001) by PharmaDrug Inc. It discusses the drug's development, preclinical study results, and regulatory interactions but does not contain financial data, earnings, management changes, or regulatory certifications. It is not a financial report, earnings release, management discussion, or regulatory filing. The content is primarily an announcement of a patent filing and related R&D progress, typical of a general regulatory or corporate announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-01-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.